Allan Hackshaw

Allan Hackshaw has more than 23 years' experience in clinical research and academic teaching. He has worked in a variety of disciplines (prevention, detection, treatment and laboratory experiments) on a range of medical disorders. He has been key investigator on successful grant applications with a total funding of more than £55 million; and has been a reviewer for or a member of committees from several funding organizations.

Publications

• López, S., Lim, E. L., Horswell, S., Haase, K., Huebner, A., Dietzen, M., . . . McGranahan, N. (2020). Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics, 52 (3), 283-293. doi:10.1038/s41588-020-0584-7
• Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., . . . TRACERx Consortium. (2019). A clonal expression biomarker associates with lung cancer mortality. Nat Med. doi:10.1038/s41591-019-0595-z
• Gore, M., Hackshaw, A., Brady, W. E., Penson, R. T., Zaino, R., McCluggage, W. G., . . . Gershenson, D. M. (2019). An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. doi:10.1016/j.ygyno.2019.03.256
• Ghorani, E., Reading, J. L., Henry, J. Y., De Massy, M. R., Rosenthal, R., Furness, A. J. S., . . . Quezada, S. A. (2019). Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer. Presented at: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). doi:10.1200/JCO.2019.37.15_suppl.2590
• Hoskin, P. J., Hopkins, K., Misra, V., Holt, T., McMenemin, R., Dubois, D., . . . Lopes, A. (2019). Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA, 322 (21), 2084-2094. doi:10.1001/jama.2019.17913
• Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., . . . Amrolia, P. J. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. doi:10.1038/s41591-019-0549-5
• Dehbi, H. -. M., & Hackshaw, A. (2019). How to use a margin of practical equivalence to include considerations other than efficacy in randomised selection trials.
• Brown, P., Tan, A. -. C., El-Esawi, M. A., Liehr, T., Blanck, O., Gladue, D. P., . . . Zhou, Y. (2019). Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database, ARTN baz085. doi:10.1093/database/baz085
• Hackshaw, A., Gershenson, D., & Ledermann, J. (2019). Mucinous Ovarian Carcinoma. New England Journal of Medicine, 381 (1), e3. doi:10.1056/NEJMc1905728
• Hutchison, I. L., Ridout, F., Cheung, S. M. Y., Shah, N., Hardee, P., Surwald, C., . . . Hackshaw, A. (2019). Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer. doi:10.1038/s41416-019-0587-2
• Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., . . . TRACERx consortium. (2019). Neoantigen-directed immune escape in lung cancer evolution. Nature. doi:10.1038/s41586-019-1032-7
• Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., . . . TRACERx Consortium. (2019). Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine. doi:10.1038/s41591-019-0593-1
• Dehbi, H. -. M., Mallick, U., Wadsley, J., Newbold, K., Harmer, C., & Hackshaw, A. (2019). Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (1), 44-51. doi:10.1016/S2213-8587(18)30306-1
• Spiro, S. G., Shah, P. L., Rintoul, R. C., George, J., Janes, S., Callister, M., . . . Hackshaw, A. (2019). Sequential screening for lung cancer in a high-risk group: randomised controlled trial. Eur Respir J. doi:10.1183/13993003.00581-2019
• Joshi, K., Robert de Massy, M., Ismail, M., Reading, J. L., Uddin, I., Woolston, A., . . . Chain, B. (2019). Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine. doi:10.1038/s41591-019-0592-2
• Lee, S. M., Upadhyay, S., Lewanski, C., Falk, S., Skailes, G., Woll, P. J., . . . Hackshaw, A. (2019). The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy. European Journal of Cancer, 120, 86-96. doi:10.1016/j.ejca.2019.07.025
• Hackshaw, A., & Dehbi, H. M. (2019). Thyroid cancer recurrence in the HiLo trial – Authors' reply. The Lancet Diabetes and Endocrinology, 7 (4), 252-253. doi:10.1016/S2213-8587(19)30088-9
• Janes, S., Dickson, J., Devaraj, A., Horst, C., Quaife, S., Levermore, C., . . . Hackshaw, A. (2019). Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test. doi:10.1016/j.jtho.2019.08.1092
• Forster, M., Hackshaw, A., De Pas, T., Cobo, M., Garrido, P., Summers, Y., . . . Lee, S. M. (2018). A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). Lung Cancer, 120, 27-33. doi:10.1016/j.lungcan.2018.03.007
• Sowter, J., Koutoukidis, D. A., Heinrich, M., McCourt, O., Hackshaw, A., Beeken, R., . . . Yong, K. (2018). Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design. Presented at: 60th Annual Meeting of the American-Society-of-Hematology (ASH). doi:10.1182/blood-2018-99-111403
• Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., . . . Gomersall, L. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. doi:10.1016/j.ccell.2018.02.010
• Brazil, L., Swampillai, A., Mak, K., Hackshaw, A., Edwards, D., Mesiri, P., . . . Short, S. C. (2018). HYDROXYCHLOROQUINE AND SHORT COURSE RADIOTHERAPY FOR ELDERLY PATIENTS WITH GLIOMA: A RANDOMISED STUDY. Presented at: 13th Meeting of the European-Association-of-Neurooncology (EANO).
• Alberro, J. A., Ballester, B., Deulofeu, P., Fabregas, R., Fraile, M., Gubern, J. M., . . . Llombart, H. A. (2018). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, 19 (1), 27-39. doi:10.1016/S1470-2045(17)30777-5
• Hackshaw, A. K., Morris, J. K., Boniface, S., Tang, J. L., & Milenkovic, D. (2018). Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. doi:10.1136/bmj.j5855
• Popat, S., Januszewski, A., Hughes, L., O'Brien, M., Ahmad, T., Lewanski, C., . . . Hackshaw, A. (2018). Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy. doi:10.1016/j.jtho.2018.08.874
• Fennell, D., Danson, S., Forster, M., Talbot, D., Woll, P., Child, J., . . . Wheeler, G. (2018). Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma. doi:10.1016/j.jtho.2018.08.415
• Mould, T. (2018). STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk Apparent stage 1 endometrial cancer. Presented at: ASCO.
• Ngai, Y., Hackshaw, A., Blackhall, F., Greystoke, A., Ahmed, S., El-Khouly, F., . . . Lee, S. M. (2018). STUDY15: a multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy for stage IV small-cell lung cancer (SCLC).
• Whelan, J., Hackshaw, A., McTiernan, A., Grimer, R., Spooner, D., Bate, J., . . . Lewis, I. (2018). Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92. Clinical sarcoma research, 8, 6. doi:10.1186/s13569-018-0093-y
• Hackshaw, A. (2018). Thyroid cancer trials. Practical Management of Thyroid Cancer: A Multidisciplinary Approach (pp. 339-355). doi:10.1007/978-3-319-91725-2_25